agvhd – Patient Worthy

Source: Pixabay

Mesoblast Reaches Endpoint for New Graft Versus Host Disease Treatment

Post author:Samuel Sachs
Post published:March 8, 2018
Post category:Graft versus Host Disease

Mesoblast Limited announced the primary endpoint success of a phase three trial on February 21st. The drug tested aims to help treat steroid refractory acute graft versus host disease. No…

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Let’s Work Together!

Keep Up to Date

Learn More